The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients.
Rosenbaum P, Artaud C, Bay S, Ganneau C, Campone M, Delaloge S, Gourmelon C, Loirat D, Medioni J, Pein F, Sablin MP, Tredan O, Varga A, Leclerc C.
Rosenbaum P, et al. Among authors: leclerc c.
Cancer Immunol Immunother. 2020 May;69(5):703-716. doi: 10.1007/s00262-020-02503-0. Epub 2020 Feb 7.
Cancer Immunol Immunother. 2020.
PMID: 32034426
Free PMC article.
Clinical Trial.